eligibility_summary
Adults ≥18 with ECOG 0–1, life ≥3 mo, advanced solid tumor (recurrent/refractory post standard therapy), ≥1 evaluable lesion, adequate organ function, combo arm requires tumor tissue, WOCBP contraception. Exclude prior same‑target therapy, recent trials/therapy, unresolved toxicity, active CNS disease or effusions, immunosuppression, autoimmunity or ILD, serious/uncontrolled illness or immunodeficiency, active HIV/TB/HBV/HCV, other active cancers, pregnancy or lactation, per investigator.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Phase I/II open-label study in advanced malignancies testing LM-101 injection alone and with toripalimab or rituximab. Drugs and mechanisms: LM-101 (IV investigational immunotherapy, mechanism/target not disclosed in the registry), Toripalimab (IV humanized IgG4 anti–PD-1 monoclonal antibody, checkpoint inhibitor that blocks PD-1/PD-L1 signaling to restore T-cell activity), Rituximab (IV chimeric IgG1 anti-CD20 monoclonal antibody, depletes CD20+ B cells via ADCC/CDC and apoptosis). Cells/pathways targeted: PD-1 on T cells (immune checkpoint pathway) to enhance antitumor immunity, CD20 on B cells to eliminate malignant or immunoregulatory B cells, LM-101’s cellular target/pathway not specified.